Advertisement

Viral Haemorrhagic Fevers Caused by Lassa, Ebola and Marburg Viruses

  • Nigel Curtis
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 582)

Keywords

Rift Valley Fever Dengue Shock Syndrome Lassa Fever Health Protection Agency Marburg Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Advisory Committee on Dangerous Pathogens. (1996). Management and control of viral haemorrhagic fevers. http://www.hpa.org.uk/infections/topics_az/VHF/ACDP_VHF_guidance.pdf.Google Scholar
  2. Baize, S. (2005). A single shot against Ebola and Marburg virus. Nat Med 11:720–1.PubMedCrossRefGoogle Scholar
  3. Baize, S., Marianneau, P., Georges-Courbot, M.C. and Deubel, V. (2001). Recent advances in vaccines against viral haemorrhagic fevers. Curr Opin Infect Dis 14:513–8.PubMedGoogle Scholar
  4. Borio, L., Inglesby, T., Peters, C.J., Schmaljohn, A.L., Hughes, J.M., Jahrling, P.B., Ksiazek, T., Johnson, K.M., Meyerhoff, A., O’toole, T., Ascher, M.S., Bartlett, J., Breman, J.G., Eitzen, E.M., Jr., Hamburg, M., Hauer, J., Henderson, D.A., Johnson, R.T., Kwik, G., Layton, M., Lillibridge, S., Nabel, G.J., Osterholm, M.T., Perl, T.M., Russell, P. and Tonat, K. (2002). Hemorrhagic fever viruses as biological weapons: medical and public health management. Jama 287:2391–405.PubMedCrossRefGoogle Scholar
  5. Centers for Disease Control and Prevention (2005a). http://www.bt.cdc.gov/agent/vhf/index.asp.Google Scholar
  6. Centers for Disease Control and Prevention (2005b). http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm.Google Scholar
  7. Centers for Disease Control and Prevention (2005c). http://www.cdc.gov/ncidod/dvrd/spb/mnpages/vhfmanual.htm.Google Scholar
  8. Eurosurveillance (2002). http://www.eurosurveillance.org/em/v07n03/v07n03.pdf.Google Scholar
  9. Eurosurveillance (2004). http://www.eurosurveillance.org/em/v09n12/0912-235.pdf.Google Scholar
  10. Feldmann, H., Jones, S., Klenk, H.D. and Schnittler, H.J. (2003). Ebola virus: from discovery to vaccine. Nat Rev Immunol 3:677–85.PubMedCrossRefGoogle Scholar
  11. Fisher-Hoch, S.P. and Mccormick, J.B. (2004). Lassa fever vaccine. Expert Rev Vaccines 3:189–97.PubMedCrossRefGoogle Scholar
  12. Geisbert, T.W. and Hensley, L.E. (2004). Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 6:1–24.PubMedCrossRefGoogle Scholar
  13. Geisbert, T.W. and Jahrling, P.B. (2004). Exotic emerging viral diseases: progress and challenges. Nat Med 10: S110–21.PubMedCrossRefGoogle Scholar
  14. Health Protection Agency (2005a). http://www.hpa.org.uk/infections/topics_az/deliberate_release/VHF/homepage.asp.Google Scholar
  15. Health Protection Agency (2005b). http://www.hpa.org.uk/infections/topics_az/VHF/menu.htm.Google Scholar
  16. Jones, S.M., Feldmann, H., Stroher, U., Geisbert, J.B., Fernando, L., Grolla, A., Klenk, H.D., Sullivan, N.J., Volchkov, V.E., Fritz, E.A., Daddario, K.M., Hensley, L.E., Jahrling, P.B. and Geisbert, T.W. (2005). Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786–90.PubMedCrossRefGoogle Scholar
  17. Klietmann, W.F. and Ruoff, K.L. (2001). Bioterrorism: implications for the clinical microbiologist. Clin Microbiol Rev 14:364–81.PubMedCrossRefGoogle Scholar
  18. Lowenstein, R. (2004). Deadly viral syndrome mimics. Emerg Med Clin North Am 22:1051–65, ix–x.PubMedCrossRefGoogle Scholar
  19. Mahanty, S. and Bray, M. (2004). Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487–98.PubMedCrossRefGoogle Scholar
  20. Mccormick, J.B., King, I.J., Webb, P.A., Johnson, K.M., O’sullivan, R., Smith, E.S., Trippel, S. and Tong, T.C. (1987). A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155:445–55.PubMedGoogle Scholar
  21. Mccormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., Elliott, L.H. and Belmont-Williams, R. (1986). Lassa fever. Effective therapy with ribavirin. N Engl J Med 314:20–6.PubMedCrossRefGoogle Scholar
  22. Ndayimirije, N. and Kindhauser, M.K. (2005). Marburg hemorrhagic fever in Angola-fighting fear and a lethal pathogen. N Engl J Med 352:2155–7.PubMedCrossRefGoogle Scholar
  23. Peters, C.J. (2005). Marburg and Ebola-arming ourselves against the deadly filoviruses. N Engl J Med 352:2571–3.PubMedCrossRefGoogle Scholar
  24. Richmond, J.K. and Baglole, D.J. (2003). Lassa fever: epidemiology, clinical features, and social consequences. Bmj 327:1271–5.PubMedCrossRefGoogle Scholar
  25. Salvaggio, M.R. and Baddley, J.W. (2004). Other viral bioweapons: Ebola and Marburg hemorrhagic fever. Dermatol Clin 22:291–302, vi.PubMedCrossRefGoogle Scholar
  26. Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y. and Nabel, G.J. (2000). Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605–9.PubMedCrossRefGoogle Scholar
  27. World Health Organization (2005a). http://www.who.int/csr/disease/en/.Google Scholar
  28. World Health Organization (2005b). http://www.who.int/topics/haemorrhagic_fevers_viral/en/.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Nigel Curtis
    • 1
    • 2
  1. 1.Department of PaediatricsUniversity of MelbourneParkvilleAustralia
  2. 2.Paediatric Infectious Diseases Unit, Department of General Medicine and Murdoch Children’s Research InstituteRoyal Children’s HospitalParkvilleAustralia

Personalised recommendations